VEGF and VEGF-C immunoreactivity, localized mainly to the cytoplasm, was weak in normal and adenoma samples, but their staining was much stronger in cancer tissues (53% for VEGF and 46% for VEGF-C; Figure 1). This evidence concerns the gene VEGFC and cancer.